Pro Share Advisors LLC Neurocrine Biosciences Inc Transaction History

Pro Share Advisors LLC

$39.7 Billion
Q3 2024

A detailed history of Pro Share Advisors LLC transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Pro Share Advisors LLC holds 20,738 shares of NBIX stock, worth $2.6 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

20,738

Previous 10,958 89.25%

Holding current value

$2.6 Million

Previous $1.51 Million 58.29%

% of portfolio

0.01%

Previous 0.0%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$114.58 - $153.15 $1.12 Million - $1.5 Million	9,780 Added 89.25%	20,738 $2.39 Million
Q2 2024 Aug 13, 2024	SELL	$130.86 - $143.19 $113,979 - $124,718	-871 Reduced 7.36%	10,958 $1.51 Million
Q1 2024 May 08, 2024	BUY	$130.4 - $143.74 $49,943 - $55,052	383 Added 3.35%	11,829 $1.63 Million
Q4 2023 Feb 14, 2024	SELL	$106.07 - $132.76 $22,486 - $28,145	-212 Reduced 1.82%	11,446 $1.51 Million
Q3 2023 Nov 13, 2023	SELL	$94.02 - $117.1 $33,377 - $41,570	-355 Reduced 2.96%	11,658 $1.31 Million
Q2 2023 Aug 10, 2023	SELL	$89.53 - $104.87 $38,408 - $44,989	-429 Reduced 3.45%	12,013 $1.13 Million
Q1 2023 May 11, 2023	SELL	$94.11 - $123.02 $271,883 - $355,404	-2,889 Reduced 18.84%	12,442 $1.26 Million
Q4 2022 Feb 02, 2023	BUY	$106.72 - $127.06 $57,095 - $67,977	535 Added 3.62%	15,331 $1.83 Million
Q3 2022 Nov 04, 2022	BUY	$92.03 - $107.81 $49,144 - $57,570	534 Added 3.74%	14,796 $1.57 Million
Q2 2022 Aug 01, 2022	SELL	$75.79 - $100.07 $381,526 - $503,752	-5,034 Reduced 26.09%	14,262 $1.39 Million
Q1 2022 May 10, 2022	SELL	$72.45 - $94.81 $362,684 - $474,618	-5,006 Reduced 20.6%	19,296 $1.81 Million
Q4 2021 Feb 08, 2022	SELL	$79.65 - $106.22 $374,195 - $499,021	-4,698 Reduced 16.2%	24,302 $2.07 Million
Q3 2021 Nov 12, 2021	BUY	$86.18 - $99.03 $125,133 - $143,791	1,452 Added 5.27%	29,000 $2.78 Million
Q2 2021 Aug 13, 2021	BUY	$89.43 - $102.27 $497,141 - $568,518	5,559 Added 25.28%	27,548 $2.68 Million
Q1 2021 May 14, 2021	BUY	$87.57 - $119.4 $516,050 - $703,624	5,893 Added 36.61%	21,989 $2.14 Million
Q4 2020 Feb 09, 2021	SELL	$86.91 - $108.33 $47,192 - $58,823	-543 Reduced 3.26%	16,096 $1.54 Million
Q3 2020 Nov 13, 2020	BUY	$96.16 - $135.15 $29,040 - $40,815	302 Added 1.85%	16,639 $1.6 Million
Q2 2020 Aug 03, 2020	BUY	$85.09 - $130.36 $168,308 - $257,852	1,978 Added 13.78%	16,337 $1.99 Million
Q1 2020 May 15, 2020	SELL	$75.11 - $113.76 $582,553 - $882,322	-7,756 Reduced 35.07%	14,359 $1.24 Million
Q4 2019 Feb 12, 2020	SELL	$86.8 - $118.57 $418,983 - $572,337	-4,827 Reduced 17.92%	22,115 $2.38 Million
Q3 2019 Nov 12, 2019	SELL	$83.82 - $101.5 $160,934 - $194,880	-1,920 Reduced 6.65%	26,942 $2.43 Million
Q2 2019 Aug 13, 2019	SELL	$72.24 - $91.27 $407,289 - $514,580	-5,638 Reduced 16.34%	28,862 $2.44 Million
Q1 2019 May 15, 2019	BUY	$69.31 - $91.53 $76,171 - $100,591	1,099 Added 3.29%	34,500 $3.04 Million
Q4 2018 Feb 14, 2019	SELL	$68.32 - $124.36 $456,650 - $831,222	-6,684 Reduced 16.67%	33,401 $2.39 Million
Q3 2018 Nov 14, 2018	BUY	$98.88 - $125.85 $16,315 - $20,765	165 Added 0.41%	40,085 $4.93 Million
Q2 2018 Aug 13, 2018	SELL	$75.3 - $105.99 $273,037 - $384,319	-3,626 Reduced 8.33%	39,920 $3.92 Million
Q1 2018 May 14, 2018	SELL	$75.88 - $92.43 $494,585 - $602,458	-6,518 Reduced 13.02%	43,546 $3.61 Million
Q4 2017 Feb 14, 2018	SELL	$58.53 - $77.59 $101,022 - $133,920	-1,726 Reduced 3.33%	50,064 $3.88 Million
Q3 2017 Nov 13, 2017	BUY	$47.97 - $61.28 $227,233 - $290,283	4,737 Added 10.07%	51,790 $3.17 Million
Q2 2017 Aug 11, 2017	BUY	N/A	47,053	47,053 $2.16 Million

Others Institutions Holding NBIX

# of Institutions

629

Shares Held

94.2M

Call Options Held

692K

Put Options Held

406K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $12B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pro Share Advisors LLC with notifications on news.

Account

Pro Share Advisors LLC Neurocrine Biosciences Inc Transaction History